# Forus

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/forus-2

- Industry: Software
- Headquarters: New York, US
- Website: www.forus.com
- Total disclosed funding: $432M
- Latest round: Series C (Oct 28, 2026)
- Investors on record: 14

## About

Forus, Inc., based in the US, specializes in automating prior authorization processes for medications, enhancing efficiency for healthcare providers while improving patient access to necessary treatments.

Forus, Inc. was founded in 2023 and is headquartered in New York, US. The company operates a prescription approval automation platform, formerly operating under the name Tandem. The company was founded by Sahir Jaggi, who currently serves as Chief Executive Officer (CEO). In September 2026, Forus, Inc. raised USD 150 million in series C funding led by Bain Capital, with participation from Thrive Capital, General Catalyst Partners, Accel, Redpoint Ventures, BoxGroup, Pear VC, Vast Ventures, Neo, Human Capital, Avra, and SV Angel. 

Forus offers a comprehensive platform that automates the entire prior authorization process for medications, supporting a wide range of drugs, insurance plans, and pharmacies across all 50 states. This solution alleviates the burden of paperwork and communication for healthcare providers, enabling them to focus more on patient care. The user base includes thousands of healthcare professionals, from independent practitioners to large health systems, who benefit from real-time visibility into medication approval processes.

Forus employs a business model that provides its services at no cost to healthcare providers and patients. This structure allows the company to facilitate transactions through partnerships with healthcare providers who integrate Forus into their existing electronic health record (EHR) systems.

The company plans to use the September 2026 funding to expand its AI medication-access platform across more medical specialties and care settings, enhance its AI agents, and grow its team.

## Funding rounds

- Series C, Oct 28, 2026, $150M — Thrive Capital, General Catalyst, Bain Capital Ventures, BoxGroup, Human Capital, Neo, Pear VC, Redpoint Ventures, SV Angel, Accel, Vast Ventures, avra
- Series C, Sep 8, 2026, $150M — Accel, Redpoint Ventures, Bain Capital, General Catalyst Partners, SV Angel, Thrive Capital, Vast Ventures, BoxGroup, Pear VC, Human Capital, Avra, Neo
- Series B, May 12, 2026, $132M — Accel, Redpoint Ventures, Bain Capital, General Catalyst Partners, Thrive Capital, BoxGroup, Pear VC

## Investors

- Accel (https://capitalatlas.ai/funds/accel) — Series B, Series C
- Redpoint Ventures (https://capitalatlas.ai/funds/redpoint-ventures) — Series B, Series C
- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series B, Series C
- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series B, Series C
- Thrive Capital (https://capitalatlas.ai/funds/thrive-capital) — Series B, Series C
- BoxGroup (https://capitalatlas.ai/funds/boxgroup) — Series B, Series C
- Pear VC (https://capitalatlas.ai/funds/pear-vc) — Series B, Series C
- SV Angel (https://capitalatlas.ai/funds/sv-angel) — Series C
- Vast Ventures (https://capitalatlas.ai/funds/vast-ventures) — Series C
- Human Capital (https://capitalatlas.ai/funds/human-capital) — Series C
- Avra (https://capitalatlas.ai/funds/avra) — Series C
- Neo — Series C
- General Catalyst — Series C
- Bain Capital Ventures — Series C